Overview Indication and application Mode of action Adverse reactions Warning and precaution Reference
ChemicalBook > CAS DataBase List > Atorvastatin calcium

Atorvastatin calcium

Overview Indication and application Mode of action Adverse reactions Warning and precaution Reference
Product Name
Atorvastatin calcium
CAS No.
134523-03-8
Chemical Name
Atorvastatin calcium
Synonyms
Atorvastatin CalciuM Trihydrate;ATORVASTATIN CA;Atrovastatin calcium;ATORVASTATIN CALCIUM SALT;Atorvastatin Ca Hydrate;Atorvastatin Calcium RS;Atorvastatin Calcium Anhydrous;Atorvastatin calciuM salt trihydrate;[r-(r*, r*)]-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylaminocarbonyl)-1h-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt;Tahor
CBNumber
CB4260130
Molecular Formula
C33H37CaFN2O5
Formula Weight
600.74
MOL File
134523-03-8.mol
More
Less

Atorvastatin calcium Property

Melting point:
176-178°C
storage temp. 
Keep in dark place,Inert atmosphere,2-8°C
solubility 
DMSO: ≥10mg/mL
form 
white powder
color 
White to Off-White
BCS Class
2
InChIKey
FQCKMBLVYCEXJB-MNSAWQCASA-L
SMILES
C(C1=C(N(CC[C@@H](O)C[C@@H](O)CC(=O)O)C(C2C=CC(F)=CC=2)=C1C1C=CC=CC=1)C(C)C)(=O)NC1C=CC=CC=1.[Ca] |&1:6,9,r|
CAS DataBase Reference
134523-03-8(CAS DataBase Reference)
EPA Substance Registry System
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1),(.beta.R,.delta.R)- (134523-03-8)
More
Less

Safety

Hazard Codes 
Xn,T,F
Risk Statements 
20/21/22-36/37/38-39/23/24/25-23/24/25-11
Safety Statements 
26-36-45-36/37-16-7
WGK Germany 
3
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H319Causes serious eye irritation

H351Suspected of causing cancer

H372Causes damage to organs through prolonged or repeated exposure

H411Toxic to aquatic life with long lasting effects

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P281Use personal protective equipment as required.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P308+P313IF exposed or concerned: Get medical advice/attention.

P314Get medical advice/attention if you feel unwell.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
10493
Product name
Atorvastatin (calcium salt)
Purity
≥98%
Packaging
5mg
Price
$25
Updated
2021/12/16
Cayman Chemical
Product number
10493
Product name
Atorvastatin (calcium salt)
Purity
≥98%
Packaging
10mg
Price
$35
Updated
2021/12/16
Cayman Chemical
Product number
10493
Product name
Atorvastatin (calcium salt)
Purity
≥98%
Packaging
25mg
Price
$50
Updated
2021/12/16
Cayman Chemical
Product number
10493
Product name
Atorvastatin (calcium salt)
Purity
≥98%
Packaging
50mg
Price
$88
Updated
2021/12/16
TRC
Product number
A791750
Product name
Atorvastatin, Calcium Salt
Packaging
25mg
Price
$60
Updated
2021/12/16
More
Less

Atorvastatin calcium Chemical Properties,Usage,Production

Overview

Atorvastatin calcium[trade name: Lipitor] is a statin-class medication used mainly for lowering the lipid as well as preventing the event associated with cardiovascular disease[1, 2]. Being similar to other kinds of statins, atorvastatin take effects by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels further increases hepatic uptake of cholesterol and reduces plasma cholesterol levels[3, 4].
Lipitor, since 1996, has become the world's best-selling medication to that point[5, 6], with more than US$125 billion in sales over approximately 14.5 years. As of 2016, in the UK, atorvastatin costs about £2 per month[5].

Indication and application

LIPITOR is mainly indicated for the treatment of cardiovascular disease and dyslipidemia due to its effect in lowering the cholesterol in the blood[7-9].
LIPITOR is a prescription medicine that lowers cholesterol in the blood. It lowers the LDL-C["bad” cholesterol] and triglycerides in your blood. It can raise your HDL-C["good" cholesterol] as well[10]. LIPITOR is for adults and children over 10 whose cholesterol does not come down enough with exercise and a low-fat diet alone. LIPITOR can lower the risk for heart attack, stroke, certain types of heart surgery, and chest pain in patients who have heart disease or risk factors for heart disease such as age, smoking, high blood pressure, low HDL-C, or heart disease in the family. LIPITOR can lower the risk for heart attack or stroke in patients with diabetes and risk factors such as eye problems, kidney problems, smoking, or high blood pressure[7-10].
As a drug for the treatment of cardiovascular, LIPITOR is indicated to reduce the risk of myocardial infarction, reduce the risk of stroke and reduce the risk for revascularization procedures and angina[7, 8, 10, 11]. Moreover, for adults patients with type II diabetes[having multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension], it is also highly effective[12, 13]. For adults diagnosed of clinically evident coronary heart disease, LIPITOR can reduce the risk of non-fatalmyocardial infarction, fatal and non-fatal stroke, revascularization procedures as well as hospitalization for CHF and angina.
As a drug for the treatment of hyperlipidemia, it is used as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TGlevels and to increase HDL-C in adult patients with primary hypercholesterolemia or in pediatric patients as well as for the treatment of adult patients with elevated serum TG levels[7, 8, 14].

Mode of action

Atorvastatin takes effect through selectively and competitively inhibiting the hepatic enzyme HMG-CoA reductase, which is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway[15, 16]. This results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations[9. 16].

Adverse reactions

The most serious adverse reactions associated with LIPITOR include Rhabdomyolysis and myopathy as well as liver enzyme abnormality[18]. Common side effects include headache, hoarseness, lower back or side pain, pain or tenderness around the eyes and cheekbones, painful or difficult urination, stuffy or runny nose[8]. Some less common side effects also include abdominal or stomach pain, back pain, belching or excessive gas, constipation, general feeling of discomfort or illness, heartburn, indigestion or stomach discomfort, lack or loss of strength, loss of appetite, nausea, shivering, sweating, trouble sleeping and vomiting[8].

Warning and precaution

Pregnant or lactation women should be disabled from using LIPITOR. Serious drug interactions can occur when certain medicines are used together with atorvastatin. So you should provide those information to your doctor before taking LIPITOR[7, 8, 17].
In rare cases, LIPITOR can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine. Avoid eating foods that are high in fat or cholesterol. LIPITOR will not be as effective in lowering your cholesterol if you do not follow a cholesterol-lowering diet plan[7, 17].
LIPITOR is not approved for use by anyone younger than 10 years old and those patients who are allergic to it, or of liver disease. Moreover, since LIPITOR may pass into breast milk and could harm a nursing baby. Do not breast-feed while you are taking this medicine[7, 17].
Patients who have a history of liver problems, muscle pain or weakness, kidney disease, diabetes. a thyroid disorder; or drink more than 2 alcoholic beverages daily should take with care[7, 17].

Reference

  1. https://www.lipitor.com
  2. Kokilambigai, K. S., R. Seetharaman, and K. S. Lakshmi. "Critical Review on the Analytical Techniques for the Determination of the Oldest Statin—Atorvastatin—in Bulk, Pharmaceutical Formulations and Biological Fluids." Critical Reviews in Analytical Chemistry 47.6(2017]:538.
  3. Teckchandani, S., et al. "Rhabdomyolysis following co-prescription of Fusidic Acid and Atorvastatin, with review of Statin Antimicrobial Drug Interactions." Scottish Medical Journal 54.3(2009]:50-50.
  4. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al.[September 2016]. "Interpretation of the evidence for the efficacy and safety of statin therapy". Lancet. 388: 2532–2561.
  5. http://www.crainsnewyork.com/article/20111228/HEALTH_CARE/111229902
  6. Maggon K: Best-selling human medicines 2002-2004. Drug Discov Today. 2005 Jun 1;10(11]:739-42.
  7. https://www.webmd.com/drugs/2/drug-3330/lipitor-oral/details
  8. https://www.drugs.com/monograph/atorvastatin-calcium.html
  9. https://www.drugbank.ca/drugs/DB01076
  10. Jukema, J. W., et al. "LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR[Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport] study. " Current Medical Research & Opinion 21.11(2005]:1865-1874.
  11. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM[April 2006]. "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial". JAMA. 
  12. Chaturvedi, S., Zivin, J., Breazna, A., Amarenco, P., Callahan, A., & Goldstein, L. B., et al.[2009]. Atorvastatin, stroke, transient ischemic attack. Neurology, 72(8], 818-819.
  13. Colhoun, H. M., et al. "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study[CARDS]: multicentre randomised placebo-controlled trial. " Lancet364.9435(2004]:685-696.
  14. Milionis, H., et al. "Th-P16:381 Treating to target patients with primary hyperlipidemia: Comparison of the effects of atorvastatin and rosuvastatin[The atoros study]." Current Medical Research & Opinion22.6(2006]:1123-1131.
  15. Youssef, S, et al. "The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. " Nature 420.6911(2002]:78-84.
  16. Black, D. M., R. G. Bakkerarkema, and J. W. Nawrocki. "An overview of the clinical safety profile of atorvastatin[lipitor], a new HMG-CoA reductase inhibitor. " Archives of Internal Medicine 158.6(1998]:577.
  17. https://www.rxlist.com/lipitor-drug.htm#side_effects_interactions

Description

Lipitor was launched in Canada, the Netherlands, the UK and the US as an orally-active hypocholesterolemic agent. It was the first pharmaceutical product ever to attain over one billion dollars in sales in its first year. It can be synthesized by a number of routes but the most efficient involves the Paal-Knorr reaction of an acetonide protected dihydroxy amino ester and a diaryl phenylacetamide diketone. Lipitor is a liver selective, reversible competitive inhibitor of HMG-CoA reductase, the rate limiting step in cholesterol biosynthesis. Lipitor monotherapy resulted in a reduction of LDL cholesterol by up to 60%. Lipitor is about 2-4 times more potent, on a dosage basis, than Simvastatin. The superior properties of Lipitor can be attributed to its greater uptake and longer duration of action in the liver. In addition to its effects on cholesterol, Lipitor is also effective in lowering triglycerides. While the mechanism is not clear, two theories proposed are: a) the decrease in cholesterol causes a concomitant increase in hepatic LDL-receptor activity (mostly B and E type) which results in a decrease in triglycerides through an increase in binding of triglycerides to VLDL and LDL, and b) the decreased level of cholesterol impairs VLDL transport of triglycerides.

Chemical Properties

White Crystalline Powder

Originator

Parke-Davis (US)

Uses

A selective, competitive HMG-CoA reductase inhibitor. Atorvastatin is the only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia.

Uses

antihyperlipidemic, HMGCoA reductase inhibitor

Uses

DMSO and EtOH soluble

Uses

The primary uses of atorvastatin is for the treatment of dyslipidemia and the prevention of cardiovascular disease.

Uses

A selective, competitive HMG-CoA reductase inhibitor. The only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia

Uses

Atorvastatin Calcium Salt Trihydrate is a compound used as standard in the method development and validation for simultaneous determination of Atorvastatin calcium (A791750) and Ezetimibe (E975000) in tablets using UV spectrophotometric, HPLC and HPTLC methods.

Definition

ChEBI: An organic calcium salt composed of calcium cations and atorvastatin anions in a 1:2 ratio.

Manufacturing Process

285 ml 2.2 M n-butyl lithium in hexane was added dropwise to 92 ml diisopropylamine at -50-60°C under nitrogen. The well stirred solutions warmed to about -20°C, then it was cannulated into a suspension of 99 g of S(+)-2-acetoxy-1,1,2-triphenylethanol in 500 ml absolute tetrahydrophuran (THF) at -70°C and the reaction mixture was allowed to warm to -10°C for 2 hours. A suspension of MgBr2 was made from 564 ml (0.63 mol) of bromine and 15.3 g of magnesium (0.63 mol) in 500 ml THF cooled to -78°C. The enolate solution was cannulated into this suspension within 30 min and was stirred for 60 min at -78°C. 150 g 5-(4-fluorophenyl)-2-(1-methylethyl)-1-(3- oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide in 800 ml absolute THF was added dropwise over 30 min, stirred 90 min at -78°C, then was added 200 ml acetic acid, this is removed to a cool bath, 500 ml of H2O was added and the mixture concentrate in vacuo at 40-50°C. After adding of 500 ml of 1:1 EtOAc/heptane the mixture was filtered. The filtrate was washed extensively with 0.5 N HCl, then several times with H2O and finally EtOAc/heptane (3:1) and cooled with dry ice to -20°C. The light brown crystalline product was dried in vacuum oven at 40°C. The yield was 194 g. 112 g of the same product was produced by evaporation of mother liquor after recrystallization and chromatographic purification on a silicagel.
162 g of this substance was suspended in methanol/THF (5:3) and was stirred with 11.7 g of sodium methoxide until everything was dissolved and kept in the freezer overnight. Later it was quenched with AcOH concentrated in vacuo, was added to 500 ml H2O and extracted twice with EtOAc (300 ml). The combined extracts was washed with saturated NaHCO3 brine and dried over anhydrous MgSO4, purified on silica-gel and gave 86.1 g of white crystals m.p. 125-126°C, αD 20=4.23° (1.17 M, CH3OH).
81 g of the last product in 500 ml absolute THF was added as quickly as possible to the mixture of 77 ml THF at diisopropylamine, 200 ml 2.2 M of nbutyl lithium and 62 ml of t-butylacetate in 200 ml THF -40-42°C under nitrogen. Stirring was continued for 4 hours at -70°C. The reaction mixture was concentrated in vacuo, the residue was taken up in EtOAc, washed with water, then saturated NH4Cl, NaHCO3 (saturated), dried over anhydrous MgSO4, filtred and the solvent evaporated.
The organic phase was dried and concentrated in vacuo to yield 73 g crude product, that was dissolved in 500 ml absolute THF, 120 ml triehtylborane and 0.7 g t-butylcarboxylic acid, 70 ml methanol and 4.5 g sodium borohydride was added. The mixture was stirred at -78°C under a dry atmosphere for 6 hours, poured slowly into 4:1:1 mixture of ice/30%H2O2/H2O and stirred overnight. CHCl3 (400 ml) was added and organic layer washed extensively with H2O until no peroxide could be found, was dried over MgSO4, filtered and was treated by chromatography on silica gel to yield 51 g. The product was dissolved in THF/methanol and saponificated with NaOH and, concentrated to remove organic solvents at room temperature, added 100 ml H2O, and extracted with Et2O twice. Organic layer was thoroughly dried and it was left at room temperature for the next 10 days, then concentrated.
Chromatography on silica gel yielded 13.2 g racemate of lactone - trans-(+/- )-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-di-diphenyl-1-[2-(tetrahydro-4- hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide. This racemate was divided by chiral synthesis which was made analogously the method in US Pat. No. 4,581,893. Then each isomer was saponificated with NaOH and purificated by HPLC. The calcium salt corresponding acid was prepared by reaction with 1 eq. of CaCl2·2H2O in water.

brand name

Lipitor (Pfizer).

Therapeutic Function

Anticholesteremic

Biological Activity

Potent HMG-CoA reductase inhibitor (IC 50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model.

Atorvastatin calcium Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Atorvastatin calcium Suppliers

Canada 5 China 498 Europe 3 Germany 4 India 88 Israel 1 Japan 1 Singapore 1 Slovakia 1 Slovenia 2 South Korea 1 The Netherlands 2 United Kingdom 14 United States 56 Global 677
JIANGXI AIFEIMU TECHNOLOGY CO.,LTD
Tel
793-33899567 13735087952
Fax
+86-570-6259526
Email
sales@afmpharm.com
Country
China
ProdList
91
Advantage
61
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4674
Advantage
55
Hubei widely chemical technology Co., Ltd.
Tel
027-83989310 18627915365
Fax
027-83989310
Email
2658488909@qq.com
Country
China
ProdList
1296
Advantage
58
Hangzhou Benoy Chemical Co., Ltd.
Tel
17342059697
Fax
QQ:2710089141
Email
sales@benoychem.com
Country
China
ProdList
391
Advantage
58
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-4000505016 13380397412
Fax
0755 28094224
Email
3001272453@qq.com
Country
China
ProdList
5047
Advantage
50
Shouguang Jiasheng Chemical Co., Ltd.
Tel
0536-7971999 18232719690
Fax
0536-7971999
Email
sgjiasheng@hotmail.com
Country
China
ProdList
347
Advantage
58
xi'an renyang Biotechnology Co., Ltd.
Tel
13299086402
Email
renyangbiotech@163.com
Country
China
ProdList
80
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Fax
86-21-50328109
Email
3bsc@sina.com
Country
China
ProdList
15839
Advantage
69
TAIYUAN RHF CO.,LTD.
Tel
+86 351 7031519
Fax
+86 351 7031519
Email
sales@RHFChem.com
Country
China
ProdList
2338
Advantage
56
Beijing HwrkChemical Technology Co., Ltd
Tel
010-89508211 18501085097
Fax
010-89508210
Email
sales.bj@hwrkchemical.com
Country
China
ProdList
8418
Advantage
55
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Fax
86-027-87531808
Email
sales@chemwish.com
Country
China
ProdList
35896
Advantage
56
Beijing Ouhe Technology Co., Ltd
Tel
010-82967028 13552068683
Fax
+86-10-82967029
Email
2355560935@qq.com
Country
China
ProdList
12390
Advantage
60
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
9976
Advantage
60
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9512
Advantage
66
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
19179
Advantage
64
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
Country
China
ProdList
42958
Advantage
64
Chemsky（shanghai）International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32321
Advantage
50
Chembon Pharmaceutical Co., Ltd.
Tel
028-84252981
Fax
+86-28-84252965
Email
sales@chembon.com.cn
Country
China
ProdList
814
Advantage
64
XiaoGan ShenYuan ChemPharm co,ltd
Tel
15527768850
Email
1791901229@qq.com
Country
China
ProdList
8836
Advantage
52
Sichuan Kulinan Technology Co., Ltd
Tel
400-1166-196 18981987031
Fax
028-84555506 800101999
Email
cdhxsj@163.com
Country
China
ProdList
11707
Advantage
57
Chengdu Green Young Biomedical Technology Co., Ltd.
Tel
86+28-85337952 18081025021
Fax
86+28-85337952
Email
greenyoung@glykj.com
Country
China
ProdList
94
Advantage
62
Hangzhou Yuhao Chemical Technology Co., Ltd
Tel
0571-82693216
Fax
+86-571-82880190
Email
info@yuhaochemical.com
Country
China
ProdList
9387
Advantage
52
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2865
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4727
Advantage
58
Wuhan Haizheng Industry & Trade Development Co. Ltd
Tel
027-8866 0053/88660577/88660578
Fax
027-8899 1911
Country
China
ProdList
1073
Advantage
55
BioBioPha Co., Ltd.
Tel
0871-65217109 13211707573;
Fax
0871-65215563
Email
y.liu@mail.biobiopha.com
Country
China
ProdList
5653
Advantage
65
Acorn PharmaTech Co., Ltd.
Tel
025-58395930
Fax
025-5861-9182
Email
sales@acornpharma.com
Country
China
ProdList
982
Advantage
60
ShangHai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847 13636370518
Fax
021-55068248
Email
shyysw007@163.com
Country
China
ProdList
4940
Advantage
60
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-83725681-603
Fax
+86 755 28094224
Country
China
ProdList
4496
Advantage
50
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1493
Advantage
55
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9891
Advantage
58
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.
Tel
025-66099280 17798518460
Fax
(1)02557626880
Email
cfzhang@aikonchem.com
Country
China
ProdList
19915
Advantage
55
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
TargetMol Chemicals Inc.
Tel
021-021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7783
Advantage
58
Shanghai TaoSu Biochemical Technology Co., Ltd.
Tel
021-33632979
Fax
021-34692979
Email
info@tsbiochem.com
Country
China
ProdList
8065
Advantage
58
Shanghai Chainpharm Bio-medical Technology Co., Ltd.
Tel
021-61727342 13611721451
Fax
021-61294107
Email
sales@chainpharm.com
Country
China
ProdList
958
Advantage
58
Cato Research Chemicals Inc.
Tel
020-81960175
Fax
+1-541-2553641
Email
min.he@cato-chem.com
Country
China
ProdList
1955
Advantage
55
Wuhan DKY Technology Co.,Ltd.
Tel
27-81302488 18007166089
Fax
027-81302088
Email
info@dkybpc.com
Country
China
ProdList
1734
Advantage
58
Hubei XinyuanShun Chemical Co., Ltd.
Tel
13971561712, 13995564702, 027-50664929
Fax
027-50664927
Email
hbeixys2001@163.com
Country
China
ProdList
3120
Advantage
55
Huainan Kedi Chemical Factory
Tel
0554-2106669
Fax
0554-2666215
Email
sales1@kedichem.com
Country
China
ProdList
4924
Advantage
55
Bide Pharmatech Ltd.
Tel
400-164-7117 13681763483
Fax
+86-21-61629029
Email
product02@bidepharm.com
Country
China
ProdList
41462
Advantage
60
Chengdu HuaXia Chemical Reagent Co. Ltd
Tel
400-1166-196 13458535857
Fax
QQ：800101999
Email
cdhxsj@163.com
Country
China
ProdList
13350
Advantage
58
Wuxi Zhongkun Biochemical Technology Co., Ltd.
Tel
0510-85629785 18013409632
Fax
051085625359
Email
sales@reading-chemicals.com
Country
China
ProdList
15178
Advantage
58
Finetech Industry Limited
Tel
027-87465837 19945049750
Fax
027-8777-2287
Email
sales@finetechnology-ind.com
Country
China
ProdList
9648
Advantage
58
Hunan HuaTeng Pharmaceutical Co., Ltd.,
Tel
400-8592883 15367835770
Fax
0731-82251112
Email
viola@huatengsci.com
Country
China
ProdList
5873
Advantage
58
Shanghai CanSpecsci Instrument Co., Ltd.
Tel
400-6087598 15021221957
Fax
4006087598-8012
Email
order@canspecsci.com
Country
China
ProdList
2045
Advantage
56
Suzhou yacoo science co.,Ltd
Tel
0512-87182056 18013166090
Fax
0512-87182056
Email
lingling.qi@yacoo.com.cn
Country
China
ProdList
7295
Advantage
60
More
Less

View Lastest Price from Atorvastatin calcium manufacturers

Sinoway Industrial co., ltd.
Product
Atorvastatin calcium 134523-03-8
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
20tons
Release date
2024-08-22
Baoji Guokang Bio-Technology Co., Ltd.
Product
Atorvastatin calcium 134523-03-8
Price
US $3600.00/Kg/Bag
Min. Order
1KG
Purity
99%
Supply Ability
1T
Release date
2021-06-03
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
Product
Atorvastatin calcium 134523-03-8
Price
US $500.00-300.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
5000
Release date
2024-08-23

134523-03-8, Atorvastatin calciumRelated Search:

Pitavastatin calcium PHENYL VALERATE Calcium Propionate Calcium carbide Calcium citrate Diphenyl ether Calcium nitrite Calcium chloride Rosuvastatin calcium Phenyl salicylate Pyrrolidine Polyvinylpyrrolidone 4-Isopropylaniline Calcium carbonate N-Vinyl-2-pyrrolidone Calcium stearate N-Methyl-2-pyrrolidone Atorvastatin Cyclic (Fluorophenyl) Impurity

  • ATORVASTATIN CALCIUM SALT
  • ATORVASTATIN CALCIUM
  • ATORVASTATIN CA
  • [r-(r*, r*)]-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylaminocarbonyl)-1h-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt
  • (3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)-1H-PYRROL-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID CALCIUM
  • (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-
  • (R,dR)-2-(4-Fluorophenyl)-,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium
  • 3S,5S-Atorvastatin Calcium
  • Bis[(3R,5R)-3,5-dihydroxy-7-[2-(1-methylethyl)-3-[(phenylamino)carbonyl]-4-phenyl-5-(4-fluorophenyl)-1H-pyrrol-1-yl]heptanoic acid]calcium salt
  • Bis[(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-yl]-3,5-dihydroxyheptanoic acid] calcium salt
  • Bis[(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-1-pyrrolyl]-3,5-dihydroxyheptanoic acid] calcium salt
  • YM-548
  • ATORVASTATINCALCUIM
  • Atrovastatin calcium
  • (3R ,5R )-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(Pheynylcarbamoyl) Pyrrol-1-yl]-3 ,5 -Dihydroheptanoic Acid, calcium salt (2:1) Trihydrate
  • 3R ,5R )-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(Pheynylcarbamoyl) Pyrrol-1-yl]-3 ,5 ydroheptanoic Acid, calcium salt (2:1) Trihydrate
  • Atorvastatin Calclum
  • ATORVASTATIN CALCIUM MM(CRM STANDARD)
  • ATORVASTATINE CADIUM
  • Atorvastatinecalcium
  • 1h-pyrrole-1-heptanoicacid,beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methy
  • calciumsalt(2:1),(r-(r*,r*))-lethyl)-3-phenyl-4-((phenylamino)carbonyl)
  • ci-981
  • delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-betcalci1h-pyrrole-1-heptanoicaci
  • pd134298-38a
  • (bR,dR)-2-(4-Fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid
  • 3S,5S-Atorvastatin
  • Alorvastin calcium
  • delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-bet calci1h-pyrrole-1-heptanoic acid
  • AtorvastatinCaliciumsalt
  • 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (.beta.R,.delta.R)-
  • (R,R)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacidhemicalciumsalt
  • Atorvastatin hemicalcium salt
  • Atorvastatin calciuM salt trihydrate
  • beta,delta-dihydroxy--2-(4-fluorophenyl)-5-(1-Methylethyl)-3-phenyl-4-((phenylaMino)carbonyl)-calciun salt(2:1)
  • Pyrrole-1-heptanoic acid
  • Atorvastatin CalciuM Trihydrate
  • (3R,5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl- 4-(Pheynylcarbamoyl)Pyrrol-1-yl]-3,5–Dihydroheptanoic Acid, calcium salt
  • Atorvastatin c
  • Atorvastatin Ca Hydrate
  • Atorvastatin, Calcium Salt - CAS 134523-03-8 - Calbiochem
  • 1H-Pyrrole-1-heptanoicacid,2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-,calciumsalt(2:1),(βR,δR)-
  • Calcium of atorvastatin
  • Atovastadine CA
  • Atorvastatin Calcium Anhydrous
  • Atorvastatin caL
  • cium saL
  • t trihydrate
  • Atorvastatin&nbsp
  • Atorvastatin aMorphous
  • atorvastatine calciuM salt
  • CalciuM (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbaMoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate
  • (βR,δR)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-Methylethyl)-3-phenyl-4-[(phenylaMino)carbonyl]-1H-pyrrole-1-heptanoic Acid CalciuM Salt
  • Atorvastatin HeMicalciuM
  • Sortis
  • Tahor
  • Atorvastatin CalciuM API
  • (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(PheynylcarbaMoyl) Pyrrol-1-yl]-3, 5 -Dihydroheptanoic Acid, calciuM salt (2:1) Trihydrate (crystal)